Non Syndromic Congenital Heart Defect and Array-CGH in Prenatal Diagnosis (CAPA)
Prospective Study for Diagnosis Utility of Array-CGH Screening in Case of Non Syndromic Congenital Heart Defect in Prenatal Diagnosis (CAPA)
Comparative genomic hybridization (CGH)-based microarrays are now often used during pregnancy in case of fetal polymalformation in order to assess significant genomic alterations. However, it is not clear whether array-CGH provide a diagnostic utility in case of isolated congenital heart defect.
This is the first prospective study aiming at defining the right chromosomal screening when a fetal isolated congenital heart defect is identified by ultrasound.
調査の概要
状態
詳細な説明
Comparative genomic hybridization (CGH)-based microarrays are now often used during pregnancy in case of fetal polymalformation in order to assess significant genomic alterations. Up to now, in case of isolated heart defect, only fetal karyotype with FISH 22q11 was usually offered. However, micro deletions or duplications could not be identified elsewhere throughout the genome. Then, in case of fetal chromosomal micro-rearrangements, parents could not be fully informed for global and neurodevelopmental prognosis. To our knowledge, clear-cut study, to assess whether array-CGH provide a diagnostic utility in case of isolated congenital heart defect, don't exist.
After informed consent, 80 women will be enrolled during two years in 2 official prenatal diagnosis centers in France. This survey is assumed to identify at least 8% of unbalanced chromosomal abnormalities. This will be also compared with 22q11 rearrangements rate.
This is the first prospective study aiming at defining the right chromosomal screening when a fetal isolated congenital heart defect is identified by ultrasound.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Rennes、フランス、35009
- Rennes University hospital
-
St Brieuc、フランス
- St Brieuc University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Pregnant woman over 18-year-old ;
- Ongoing health insurance ;
- Informed consent ;
- Prenatal samples from amniotic fluid ;
- Isolated congenital heart defect.
Exclusion Criteria:
- Transposition of great arteries ;
- Amniotic fluid sample refusal.
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Identification a significant rate of chromosomal imbalances on ACPA > 8%
時間枠:J0
|
J0
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
To compare rates of abnormalities identified by karyotype FISH 22q11 versus ACPA
時間枠:J0
|
J0
|
To compare cardiac ultrasound prenatal data with postnatal data including pathological data (if TOP)
時間枠:J0
|
J0
|
To compare the nature of chromosomal imbalances with the type of MCC
時間枠:J0
|
J0
|
協力者と研究者
捜査官
- 主任研究者:Laurent Pasquier, PH、Rennes University hospital
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。